COST-EFFECTIVENESS MODELING OF LURBINECTEDIN AS A SECOND-LINE THERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

被引：0
|
作者：
Su, W. [1 ]
Rengarajan, B. [2 ]
Profant, D. [2 ]
Mayo, K. [1 ]
Groff, M. [3 ]
Tremblay, G. [3 ]
Ganti, A. K. [4 ]
机构：
[1] Jazz Pharmaceut, Philadelphia, PA USA
[2] Jazz Pharmaceut, Palo Alto, CA USA
[3] Cytel Inc, Cambridge, MA USA
[4] VA Nebraska Iowa Hlth Care Syst, Omaha, NE USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE152
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [41] Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
    Eckardt, J
    Depierre, A
    Ardizzoni, A
    VonPawel, J
    Fields, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1041 - 1041
  • [42] OUTCOMES OF SMALL CELL LUNG CANCER (SCLC) PATIENTS TREATED WITH SECOND-LINE CHEMOTHERAPY (SL): A RETROSPECTIVE ANALYSIS OF 166 PATIENTS
    Garassino, M. C.
    Califano, R.
    Michetti, G.
    Borgonovo, K.
    Lo Dico, M.
    Fatigoni, S.
    Martelli, O.
    Ghidini, A.
    Bareggi, C.
    Torri, V.
    LUNG CANCER, 2009, 64 : S62 - S62
  • [43] Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL): A retrospective analysis of 166 patients
    Garassino, M. C.
    Michetti, G.
    Lo Dico, M.
    Califano, R.
    Aglione, S.
    Borgonovo, K.
    Mancuso, A.
    Galetta, D.
    Gallerani, E.
    Collova, E.
    Torri, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    K. Zhou
    F. Wen
    P. Zhang
    J. Zhou
    H. Chen
    H. Zheng
    Y. Yang
    Q. Li
    Clinical and Translational Oncology, 2017, 19 : 1117 - 1124
  • [45] Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.
    Shim, Joosung Gabriel
    Lim, Sun Min
    Cho, Byoung Chul
    Hong, Min Hee
    Lee, Jii Bum
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 211 - 211
  • [46] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [47] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    Zhou, K.
    Wen, F.
    Zhang, P.
    Zhou, J.
    Chen, H.
    Zheng, H.
    Yang, Y.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (09): : 1117 - 1124
  • [48] A PHASE II STUDY OF WEEKLY PACLITAXEL PLUS GEMCITABINE AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OR RECURRENT SMALL CELL LUNG CANCER (SCLC)
    Kim, H. T.
    Yun, T.
    Han, J.
    Choi, H. L.
    Kim, H. Y.
    Lee, J. S.
    LUNG CANCER, 2009, 64 : S62 - S62
  • [49] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    VALUE IN HEALTH, 2017, 20 (09) : A871 - A871
  • [50] EFFICACY AND COST-EFFECTIVENESS OF SECOND-LINE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
    Zhou, K.
    VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
12345